Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 2554

Drug Profile

SHR 2554

Alternative Names: EBI 2554; SHR2554

Latest Information Update: 20 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer
  • Phase I Lymphoma

Most Recent Events

  • 20 Nov 2018 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in China (PO) (NCT03741712)
  • 20 Nov 2018 Phase-I/II clinical trials in Prostate cancer (Monotherapy, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03741712)
  • 10 Aug 2018 Phase-I clinical trials in Lymphoma (Refractory metastatic disease, Second-line therapy or greater) in China (PO) (NCT03603951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top